Core Insights - Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, bringing over 25 years of experience in the biopharmaceutical industry [1][2] - Dr. Ramanan's expertise includes facilitating product launches, establishing scalable operations, and enabling corporate transactions, which will support Immatics' growth and commercialization efforts [1][2] - The company is focused on advancing its PRAME cell therapy, anzu-cel, towards commercialization for patients with metastatic melanoma [2][3] Company Overview - Immatics is a clinical-stage biopharmaceutical company and a global leader in precision targeting of PRAME, a target expressed in over 50 cancers [3] - The company has a robust clinical pipeline with the broadest PRAME franchise, including TCR T-cell therapies and TCR bispecifics [3]